[ad_1]
|
AstraZeneca vaccine prevention rate 70%
On the 23rd (local time), according to CNBC and BBC, AstraZeneca announced the results of an interim analysis of the phase 3 clinical trial for the COVID-19 vaccine, which was based on the same content with the University of Oxford. The company explained that it showed 90% and 62% preventive effects in the two trials with different dosing methods.
Consequently, AstraZeneca plans to focus on the test method that showed 90% efficacy. Andrew Pollard, the lead researcher who led the trial, said: “If you use a method that works 90%, you can give the vaccine to more people.”
Today’s announcement was an intermediate result of a survey of just 131 subjects out of 20,000 test participants. AstraZeneca aims to release the final results of the phase 3 clinical trial before Christmas on the 25th of next month.
Earlier, AstraZeneca said in an article published in the medical journal ‘Lancet’ that “a strong immune response appeared” in phase 2 clinical trials involving 560 people. In particular, a strong shape was expected to form in the elderly.
“The efficacy and safety of this vaccine is very good,” said Pascal Sorio, executive director. “It will be an important milestone that can directly affect the public health crisis.” “We are encouraging to produce up to 3 billion doses of vaccines next year,” he added. “As soon as the clinical trial is over, we will send data to authorities around the world.”
Pfizer, much cheaper than the modder or the vaccine
The advantage of the AstraZeneca vaccine is its price. The price of the vaccine is known to be 3 pounds (about 4,400 won per adult) per dose (one dose per adult). Compared to the modern vaccine, which costs between $ 32-37 per dose (35,000-41,000 won), it is 10 times cheaper. The Pfizer vaccine costs $ 19.5 per dose (about 21,000 won). “The effect of the vaccine is somewhat less than that of Pfizer and Modena, but the price is much cheaper and storage and transportation are easy,” said foreign media.
The World Health Organization (WHO) expressed its welcome. “We welcome the efforts of AstraZeneca and Oxford to make vaccines inexpensive and easy to store,” said Sumya Swaminatan, WHO Chief Scientist.
The share price of AstraZeneca, which is listed on the NASDAQ, is falling due to relatively low immune effects. It is trading at $ 53.59 per share, 3.08% less than the previous trading day at 43 minutes that day. However, thanks to distribution advantages, expectations for vaccines are increasing and the overall rate is increasing. The Dow is currently up 0.47%.